Cytoskeleton Dysfunction Comparison -- AD/PD/ALS/FTD/HD

Cytoskeleton Dysfunction in Neurodegenerative Diseases

> A comprehensive comparison of cytoskeletal alterations across AD, PD, ALS, FTD, and HD, with emphasis on microtubule dysfunction, motor protein impairment, and therapeutic strategies

Overview

The cytoskeleton provides structural support, intracellular transport, and cellular dynamics in neurons. Cytoskeletal dysfunction disrupts axonal transport, leads to dendritic spine abnormalities, and contributes to neuronal death. The neuronal cytoskeleton consists of three major filament systems: microtubules, actin filaments (microfilaments), and intermediate filaments. Each system plays distinct yet interconnected roles in maintaining neuronal architecture, facilitating intracellular transport, and enabling dynamic remodeling essential for synaptic plasticity and signal transmission. Dysregulation of any component triggers a cascade of pathological changes that ultimately result in neurodegeneration [@gong2005][@takao2004].

Comparison Matrix

Cytoskeleton Dysfunction in Neurodegenerative Diseases

> A comprehensive comparison of cytoskeletal alterations across AD, PD, ALS, FTD, and HD, with emphasis on microtubule dysfunction, motor protein impairment, and therapeutic strategies

Overview

The cytoskeleton provides structural support, intracellular transport, and cellular dynamics in neurons. Cytoskeletal dysfunction disrupts axonal transport, leads to dendritic spine abnormalities, and contributes to neuronal death. The neuronal cytoskeleton consists of three major filament systems: microtubules, actin filaments (microfilaments), and intermediate filaments. Each system plays distinct yet interconnected roles in maintaining neuronal architecture, facilitating intracellular transport, and enabling dynamic remodeling essential for synaptic plasticity and signal transmission. Dysregulation of any component triggers a cascade of pathological changes that ultimately result in neurodegeneration [@gong2005][@takao2004].

Comparison Matrix

| Feature | AD | PD | ALS | FTD | HD |
|---------|-----|-----|------|------|-----|
| Microtubule Integrity | Tau hyperphosphorylation, MT depolymerization | alpha-Syn binds MT, disrupts transport | MT destabilization, dynactin mutations | Tau pathology, MT dysfunction | Mutant HTT disrupts MT motors |
| Motor Protein Function | Kinesin/dynactin impairment | Kinesin dysfunction | DYNC1H1, DCTN1 mutations | Tau affects transport | HTT cargo function disrupted |
| Axonal Transport Deficit | Early transport failure | Progressive transport failure | Early and severe transport failure | Transport deficits | Transport impairment |
| Actin Dynamics | Spine morphology changes | Actin binding by alpha-syn | Cytoskeletal remodeling | Actin abnormalities | Actin cytoskeleton altered |
| Intermediate Filaments | NF phosphorylation changes | NF aggregation | NF inclusions, peripherin | Cytoskeletal changes | NF abnormalities |
| Tau Pathology | Primary driver | Tau co-pathology | Tau in some cases | Primary in 3R/4R tau | Tau alterations |

Molecular Architecture of the Neuronal Cytoskeleton

Microtubule Structure and Function

Microtubules are hollow cylindrical polymers composed of alpha- and beta-tubulin heterodimers that assemble into 13 protofilaments forming a 25 nm diameter tube. In neurons, microtubules serve as tracks for long-range intracellular transport, with polarity determining direction: plus ends (axon) and minus ends (cell body). The microtubule network is particularly dense in axons where it spans the entire length from soma to synaptic terminals [@baas1991][@dixon1981].

Neurons express multiple tubulin isotypes (betaI, betaII, betaIII, betaIV) with distinct spatial distributions. Post-translational modifications including acetylation, detyrosination, polyglutamylation, and phosphorylation regulate microtubule stability and motor protein binding. Axonal microtubules are typically more stable (acetylated) while dendritic microtubules display mixed stability patterns.

Actin Filament Organization

Actin filaments form a submembranous network beneath the plasma membrane and populate dendritic spines, where they undergo rapid polymerization and depolymerization underlying synaptic plasticity. The spine actin cytoskeleton consists of branched networks (Arp2/3-mediated) and linear filaments (formin-mediated), with myosin motors generating tension and facilitating cargo transport in the spine cytoplasm. Actin dynamics are regulated by numerous binding proteins including cofilin, profilin, and capping proteins.

Intermediate Filament Network

Neurofilaments (NF-L, NF-M, NF-H) constitute the major intermediate filament system in large projection neurons, with phosphorylation of the tail domains modulating assembly state and transport. Peripherin forms intermediate filaments in peripheral neurons, while vimentin and alpha-internexin are expressed during development. The intermediate filament network provides structural stability and contributes to axonal caliber determination.

Disease-Specific Mechanisms

Alzheimer's Disease: Tau-Mediated Microtubule Disruption

Tau is a microtubule-associated protein (MAP) primarily expressed in neurons. In the CNS, six tau isoforms are produced by alternative splicing of the MAPT gene, containing 3 or 4 repeat domains (3R or 4R). Over 40 phosphorylation sites have been identified on tau, with pathological hyperphosphorylation driven by kinases (GSK-3beta, CDK5, MARK, CK1, CaMKII) and reduced phosphatase activity (PP2A accounts for ~70% of tau dephosphorylation) [@kahlson2021][@chun2003].

Key mechanisms:

• Tau Hyperphosphorylation: PHFs/tangles sequester normal tau, disrupting MT binding
• MT Depolymerization: Hyperphosphorylated tau loses MT stabilizing function
• Axonal Transport Failure: Reduced kinesin-based transport of vesicles and organelles precedes tangle formation [@stamer2002][@umann2019]
• Energy Depletion: Mitochondrial transport impairment leads to energy crisis
• TFEB Nuclear Translocation Reduced: Impaired lysosomal biogenesis compounds clearance defects

Parkinson's Disease: Alpha-Synuclein Cytoskeletal Interactions

Alpha-synuclein directly binds to microtubules through its N-terminal region, with pathological mutations (A53T, A30P) enhancing this interaction. The binding affinity increases with concentration and is modulated by Ser129 phosphorylation.

Key mechanisms:

• Alpha-syn oligomers compete with tau for MT binding
• Direct inhibition of kinesin motor activity through ATPase interference
• Kinesin-1 and kinesin-3 families both affected
• Dynein function impaired through dynactin interactions
• "Dying-back" neurodegeneration beginning at nerve terminals consistent with progressive transport failure

Lewy Body Components: Contain neurofilament proteins (NF-L, NF-M, NF-H) in periphery, tubulin and MAPs co-aggregated with alpha-syn, and altered actin-binding proteins (cofilin, profilin).

ALS Cytoskeletal Pathology

ALS shows severe cytoskeletal dysfunction with multiple gene involvement.

TDP-43 and Cytoskeleton: TDP-43 regulates splicing of cytoskeletal genes. Over 30 cytoskeletal-related genes are TDP-43 targets including tropomyosin (actin-binding), ankyrins (membrane-cytoskeleton linkers), and spectrins (membrane stabilization). Loss of nuclear TDP-43 disrupts alternative splicing of these targets.

ALS-Specific Cytoskeletal Genes:

• Dynactin (DCTN1): p50 subunit mutations cause transport deficits and reduced dynein processivity
• Cytoplasmic Dynein (DYNC1H1): Motor domain mutations impair force generation with dominant inheritance
• Profilin 1 (PFN1): Mutations reduce actin polymerization, disrupted dendritic spine morphology, associated with ALS-FTD spectrum

Frontotemporal Dementia: Tauopathies and VCP Pathology

FTD encompasses multiple clinical syndromes with distinct cytoskeletal pathologies:

• CBD: 4R tau predominant
• PSP: 4R tau with globose NFTs
• Pick's disease: 3R tau predominant
• FTD with MAPT mutations: Inherited tauopathy with 3R/4R imbalance

Huntington's Disease: Huntingtin and Transport

Wild-type huntingtin is a large scaffolding protein (~350 kDa) essential for vesicular transport.

Cargo Adaptor Function: HTT binds to kinesin and dynein via adaptor proteins, serving as a platform for transport complexes. Specific cargoes include BDNF vesicles, synaptic vesicles, mitochondria, endosomes, and autophagosomes.

Mutant HTT Effects on Transport:

• Expanded polyQ tract disrupts protein interactions
• HTT fragmentation impairs transport complex formation
• Transcriptional dysregulation reduces transport protein expression
• Energy deficits impair motor function
• Reduced BDNF transport to nerve terminals

Therapeutic Approaches

Transport-Modifying Strategies

| Strategy | Target | Disease | Status |
|----------|--------|---------|--------|
| Tau Aggregation Inhibitors | Tau oligomers | AD, FTD | Clinical trials |
| Alpha-Syn Aggregation Inhibitors | Alpha-syn oligomers | PD | Preclinical |
| HTT Lowering | Mutant HTT | HD | Clinical trials |
| Microtubule Stabilizers | MT integrity | AD, PD | Preclinical |
| Kinesin Activators | Motor function | Multiple | Research |
| Dynein Modulators | Retrograde transport | ALS | Research |

Advanced Microtubule-Stabilizing Agents

• TPI-287 (Abraxane analog): Brain-penetrant taxane derivative, Phase 1 trials for AD
• Epothilone D (BMS-241027): Natural product MT stabilizer, tested in AD clinical trials; discontinued due to safety
• Dictyostatin and discodermolide: Marine sponge-derived compounds with CNS delivery potential
• LMTX (TRx0237): Tau aggregation inhibitor, completed Phase 3 trials

Molecular Motor Engineering

• Kinesin-1 activators: Small molecules enhancing ATPase activity and processivity
• Kinesin light chain modulators: Peptides stabilizing kinesin-cargo interactions
• Dynactin stabilizers: Agents enhancing dynein-dynactin processivity
• BICD2 modulators: Targeting dynein-cargo adaptor proteins
• HDAC6 inhibitors: Regulate tubulin acetylation and transport

Gene Therapy Approaches

• MAP6 overexpression: Neuronal MT-stabilizing protein for enhancing transport
• TAU gene silencing: ASOs against mutant MAPT for FTD
• AAV9-mediated delivery: Express MAPs or motor co-factors in neurons
• CRISPR-Cas9: Correct pathogenic MAPT or HTT mutations
• Huntingtin-lowering ASOs: Multiple clinical trials reducing mutant HTT expression

Biomarkers

Transport-Related Biomarkers

| Biomarker | Disease | Source | Status |
|-----------|---------|--------|--------|
| NfL in CSF | All | Axonal damage | Clinical |
| p-tau181 | AD, FTD | Tau pathology | Clinical |
| Alpha-syn oligomers | PD | Alpha-syn pathology | Research |
| TDP-43 fragments | ALS, FTD | TDP-43 pathology | Research |

Imaging Biomarkers

• Diffusion Tensor Imaging: Detects white matter tract damage from transport deficits
• PET with MT-Targeted Tracers: Emerging probes for MT integrity
• Functional MRI: Assesses connectivity changes from transport deficits

Cross-Links

• [Axonal Transport Dysfunction Comparison](/mechanisms/axonal-transport-dysfunction-comparison)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [TDP-43](/proteins/tdp-43)
• [Huntingtin](/proteins/huntingtin-protein)
• [Actin Cytoskeleton Dynamics](/mechanisms/actin-cytoskeleton-dynamics)
• [Synaptic Dysfunction Comparison](/mechanisms/synaptic-dysfunction-comparison)
• [Mitochondrial Dysfunction Comparison](/mechanisms/mitochondrial-dysfunction-comparison)